BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 29, 2002
 |  BioCentury  |  Strategy

Ebsworth's quick decision on Zavesca

Rather than develop a post-marketing pharmacovigilance system for its Zavesca Gaucher disease treatment and build a sales and marketing force from the ground up, Oxford Glycosciences plc has opted to put these launch responsibilities in the hands of Actelion SA in exchange for a majority share of the European revenues.

"We looked at the infrastructure costs of setting up a European sales team and all the component requirements," said David Ebsworth, the former head of pharmaceuticals at Bayer AG who in May became CEO of Oxford Glycosciences (LSE:OGS; OGSI, Oxford, U.K.). "Selling Zavesca ourselves in Europe just did not make commercial sense."

The oral N-butyldeoxynojirimycin glucosyltransferase inhibitor received an approval recommendation last week from the EU's CPMP to treat mild to moderate type 1 Gaucher patients deemed unsuitable for enzyme replacement therapy.

Zavesca would not have received final European approval until OGS had a post-marketing vigilance system up and running, according to Actelion spokesperson Roland Haefeli. But Actelion (SWX:ATLN, Allschwil, Switzerland) already has a vigilance system in place for its Tracleer bosentan oral endothelin...

Read the full 872 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >